Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-119 + Paclitaxel in Advanced Solid Tumors
NCT02134067Phase 1Terminated
- Sponsor
- Taiho Oncology
- Start
- Aug 2014
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAS-119 in solid tumor (advanced stage), sponsored by Taiho Oncology. Primary endpoint: Safety and tolerability of TAS-119 in combination with paclitaxel up to 3 years. Started Aug 2014; status: terminated.
02
Drugs
TAS-119
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02134067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02134067.